This SSP applies to the following medicine:

<table>
<thead>
<tr>
<th>Name of medicine (including strength and formulation)</th>
<th>Premique® Low Dose 0.3mg/1.5mg modified-release tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Legal category</td>
<td>POM</td>
</tr>
</tbody>
</table>

1. Details of medication to be supplied under this SSP

<table>
<thead>
<tr>
<th>Name of medicine (including formulation and strength to be supplied)</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quantity of this formulation (if applicable)</td>
<td>Total quantity supplied under this protocol to be equivalent to three months’ supply of the prescribed medicine.</td>
</tr>
<tr>
<td>Substitution results in a change to whether the use is licenced</td>
<td>No</td>
</tr>
</tbody>
</table>

Scope for which this Serious Shortage Protocol (SSP) applies

<table>
<thead>
<tr>
<th>The SSP applies to the following parts of the UK</th>
<th>UK-wide</th>
</tr>
</thead>
</table>

Clinical situation to which this Serious Shortage Protocol (SSP) applies

<table>
<thead>
<tr>
<th>Scope of SSP</th>
<th>All NHS and private prescriptions. This protocol allows for the quantity supplied to be less than the number of days prescribed on the original prescription.</th>
</tr>
</thead>
</table>
### Criteria for inclusion
- The patient presents with a valid prescription (meeting the requirements of the Human Medicines Regulations 2012) for an amount greater than three months' supply for Premique® Low Dose 0.3mg/1.5mg modified-release tablets.
- The patient/carer is aware that in accordance with this SSP, no further supply can be made from the same prescription above the three-month quantity.

### Criteria for exclusion
- The patient presents with a prescription for a medicine other than Premique® Low Dose 0.3mg/1.5mg modified-release tablets.
- The patient presents a prescription which is not valid.
- The patient presents a prescription for Premique® Low Dose 0.3mg/1.5mg modified-release tablets for an amount less than or equivalent to three months' supply.
- The patient/carer does not consent to receiving the medicine supplied in accordance with this SSP.

### Cautions including any relevant action to be taken
None

### Special considerations for specific populations of patients
None

### Action to be taken if the patient is excluded
None

### Action to be taken if the patient or carer declines the supply
If a patient/carer declines to receive the medicine under this SSP, the pharmacist should use their professional judgement to determine if other courses of action are appropriate whilst taking into consideration wider supply issues. If this does not address their concerns, the patient/carer should be referred back to their prescriber for advice.

### Valid from: 29/04/2022
### Expiry date: 29/07/2022
### Reference number: SSP021
### Version number: 1.0

Any queries regarding the content of this SSP which was issued by the Secretary of State for Health and Social Care, should be addressed to NHS Prescription Services.

You can get in contact by:
**Email:** nhsbsa.prescriptionservices@nhsbsa.nhs.uk
2. Conditions under which this Serious Shortage Protocol (SSP) will operate

- The decision to supply any medicine under this protocol rests with the individual registered pharmacist who must abide by the protocol.
- Whilst pharmacy staff may support the dispensing process of the protocol, this must be carried out under the supervision of the registered pharmacist.
- Pharmacists using this SSP must ensure that it is only used within its authorised dates and within the criteria set out within the SSP. Pharmacists must check that they are using the current version of the SSP, particularly when referring to a hard copy version. Amendments may become necessary prior to the published expiry date. Current versions of SSP templates can be found at [https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/serious-shortage-protocols-ssps](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/serious-shortage-protocols-ssps).
- Users must not alter, amend or add to the content of this document; such action will invalidate the SSP.

### Ministerial ratification by:

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria Caulfield</td>
<td>Minister</td>
<td>[Signature]</td>
<td>29/4/2022</td>
</tr>
</tbody>
</table>
ADDENDUM
Supporting information on notifying other healthcare professionals

- Any items supplied in accordance with an SSP in response to an NHS prescription also needs to be supplied in accordance with NHS Pharmaceutical and Local Pharmaceutical Services Regulations.

- Those Regulations provide that where a therapeutic equivalent is supplied, a pharmacist will need to inform a patient’s GP practice. This would generally be expected within the next working day, but further guidance would be given in any case where this applied.

- Where a different quantity, an alternative pharmaceutical form, an alternative strength or a generic equivalent is provided, it may not always be necessary that the patient’s prescriber is informed, as the existence of the SSP may be enough for the prescriber to be aware that these changes in dispensing may take place, unless national arrangements agreed with the relevant representative bodies state otherwise. However, guidance may be issued on particular SSPs to indicate that prescribers should be informed of any patients that receive supply under it.

- In the absence of any preferred local alternate communication channels, all feedback to prescribers should be sent by NHSmail. The NHS 111 Directory of Service finder is a way for pharmacies to look up the email address of the patient’s GP.